Kanada - enska - Health Canada

mylan pharmaceuticals ulc - topotecan (topotecan hydrochloride) - powder for solution - 4mg - topotecan (topotecan hydrochloride) 4mg - antineoplastic agents

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

agila australasia pty ltd - topotecan hydrochloride -

Kanada - enska - Health Canada

teva canada limited - topotecan (topotecan hydrochloride) - powder for solution - 1mg - topotecan (topotecan hydrochloride) 1mg - antineoplastic agents

Kanada - enska - Health Canada

teva canada limited - topotecan (topotecan hydrochloride) - powder for solution - 4mg - topotecan (topotecan hydrochloride) 4mg - antineoplastic agents

Bandaríkin - enska - NLM (National Library of Medicine)

actavis pharma, inc. - topotecan hydrochloride (unii: 956s425zcy) (topotecan - unii:7m7ykx2n15) - topotecan hydrochloride for injection, as a single agent, is indicated for the treatment of patients with metastatic ovarian cancer after disease progression on or after initial or subsequent chemotherapy. topotecan hydrochloride for injection, as a single agent, is indicated for the treatment of patients with small cell lung cancer (sclc) with platinum-sensitive disease who progressed at least 60 days after initiation of first-line chemotherapy. topotecan hydrochloride for injection, in combination with cisplatin, is indicated for the treatment of patients with stage iv-b, recurrent, or persistent cervical cancer not amenable to curative treatment. topotecan hydrochloride is contraindicated in patients who have a history of severe hypersensitivity reactions to topotecan. reactions have included anaphylactoid reactions [see adverse reactions (6.2)]. risk summary based on animal data and its mechanism of action, topotecan hydrochloride can cause fetal harm when administered to a pregnant woman. there are no av

Belgía - enska - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

accord healthcare b.v. - topotecan hydrochloride 1,0865 mg/ml - eq. topotecan 1 mg/ml - concentrate for solution for infusion - 1 mg/ml - topotecan hydrochloride - topotecan

Belgía - enska - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

accord healthcare b.v. - topotecan hydrochloride 1,0865 mg/ml - eq. topotecan 1 mg/ml - concentrate for solution for infusion - 1 mg/ml - topotecan hydrochloride - topotecan

Singapúr - enska - HSA (Health Sciences Authority)

novartis (singapore) pte ltd - topotecan hcl eqv topotecan - injection, powder, for solution - 4 mg/vial - topotecan hcl eqv topotecan 4 mg/vial

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty limited - topotecan hydrochloride -

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - topotecan hydrochloride, quantity: 4.346 mg - injection, powder for - excipient ingredients: sodium hydroxide; tartaric acid; hydrochloric acid; mannitol - topotecan ag for injection is indicated as single agent therapy for the treatment of patients with: - small cell lung carcinoma after failure of first line chemotherapy; - metastatic carcinoma of the ovary after failure of first-line or subsequent therapy. topotecan ag for injection is indicated in combination with cisplatin for the treatment of patients with: - histologically confirmed stage iv-b, recurrent, or persistent carcinoma of the cervix, which is not amenable to curative treatment with surgery and/or radiation therapy.